The effect of bebtelovimab on clinical outcomes in patients with COVID-19: A meta-analysis
J Infect
.
2023 Jul;87(1):68-71.
doi: 10.1016/j.jinf.2023.04.010.
Epub 2023 Apr 19.
Authors
Jie Luo
1
,
Toni Li
2
,
Changying Liu
3
,
Yushu Wang
4
,
Carolyn Tran
5
,
Guangyu Ao
6
Affiliations
1
Department of Nephrology, Chengdu First People's Hospital, Chengdu, Sichuan, China.
2
School of Medicine, Queen's University, Kingston, Canada.
3
Department of Geriatrics, People's Liberation Army, The General Hospital of Western Theater Command, Chengdu, China.
4
Chengdu West China Clinical Research Center, Chengdu, Sichuan, China.
5
Schulich School of Medicine & Dentistry, Western University, London, Canada.
6
Department of Nephrology, Chengdu First People's Hospital, Chengdu, Sichuan, China. Electronic address: agy1990418@163.com.
PMID:
37085048
PMCID:
PMC10114314
DOI:
10.1016/j.jinf.2023.04.010
No abstract available
Publication types
Meta-Analysis
Letter
Comment
MeSH terms
Antibodies, Neutralizing* / therapeutic use
COVID-19*
Humans
Substances
Antibodies, Neutralizing
bebtelovimab